Development of a histone deacetylase 6 inhibitor and its biological effects

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 39, 2013, Pages 15704-15709

  Lee, Ju Hee ^a   Mahendran, Adaickapillai ^b   Yao, Yuanshan ^b   Ngo, Lang ^a   Venta Perez, Gisela ^a   Choy, Megan L ^a   Kim, Nathaniel ^b   Ham, Won Seok ^b   Breslow, Ronald ^b   Marks, Paul A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Anticancer agents; Drug discovery; Epigenetics based chemotherapy

Indexed keywords

ETOPOSIDE; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; RICOLINOSTAT; TUBACIN; UBIQUITIN; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG POTENCY; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANTICANCER AGENTS; DRUG DISCOVERY; EPIGENETICS-BASED CHEMOTHERAPY;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL SURVIVAL; DNA BREAKS, DOUBLE-STRANDED; DOXORUBICIN; ETOPOSIDE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; MICE; TREHALOSE; TUBULIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884631782     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1313893110     Document Type: Article

References (28)

1. Marks PA (2010) Histone deacetylase inhibitors: A chemical genetics approach to understanding cellular functions. Biochim Biophys Acta 1799(10-12): 717-725.
2. Li Y, Shin D, Kwon SH (2013) Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes. FEBS J 280(3):775-793.
3. Valenzuela-Fernández A, Cabrero JR, Serrador JM, Sánchez-Madrid F (2008) HDAC6: A key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends Cell Biol 18(6): 291-297.
4. Kovacs JJ, et al. (2005) HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 18(5):601-607.
5. Parmigiani RB, et al. (2008) HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proc Natl Acad Sci USA 105(28):9633-9638.
6. Zhang X, et al. (2007) HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol Cell 27(2):197-213.
7. Hubbert C, et al. (2002) HDAC6 is a microtubule-associated deacetylase. Nature 417(6887):455-458.
8. Kawaguchi Y, et al. (2003) The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115(6): 727-738.
9. Boyault C, et al. (2007) HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev 21(17):2172-2181.
10. Kwon S, Zhang Y, Matthias P (2007) The deacetylase HDAC6 is a novel critical component of stress granules involved in the stress response. Genes Dev 21(24): 3381-3394.
11. Butler LM, et al. (2000) Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60(18):5165-5170.
12. Santo L, et al. (2012) Preclinical activity, pharmacodynamic and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 119(11):2579-2589.
13. Smil DV, et al. (2009) Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors. Bioorg Med Chem Lett 19(3):688-692.
14. Bergman JA, et al. (2012) Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. J Med Chem55 (22) 9891-9899.
15. Inks ES, Josey BJ, Jesinkey SR, Chou CJ (2012) A novel class of small molecule inhibitors of HDAC6. ACS Chem Biol 7(2):331-339.
16. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL (2003) Domainselective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 100(8):4389-4394.
17. Estiu G, et al. (2008) Structural origin of selectivity in class II-selective histone deacetylase inhibitors. J Med Chem 51(10):2898-2906.
18. Dallavalle S, Pisano C, Zunino F (2012) Development and therapeutic impact of HDAC6-selective inhibitors. Biochem Pharmacol 84(6):756-765.
19. Butler KV, et al. (2010) Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J Am Chem Soc 132(31):10842-10846.
20. Marks PA, Breslow R (2007) Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25(1): 84-90.
21. Bradner JE, et al. (2010) Chemical phylogenetics of histone deacetylases. Nat Chem Biol 6(3):238-243.
22. Lee JH, Choy ML, Ngo L, Foster SS, Marks PA (2010) Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci USA 107(33):14639-14644.
23. Namdar M, Perez G, Ngo L, Marks PA (2010) Selective inhibition of histone deacetylase (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc Natl Acad Sci USA 107(46):20003-20008.
24. Lee JY, et al. (2010) HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. EMBO J 29(5):969-980.
25. Hideshima T, et al. (2005) Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 102(24):8567-8572.
26. Sarkar S, Davies JE, Huang Z, Tunnacliffe A, Rubinsztein DC (2007) Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J Biol Chem 282(8):5641-5652.
27. Simbulan-Rosenthal CM, Rosenthal DS, Iyer S, Boulares AH, Smulson ME (1998) Transient poly(ADP-ribosyl)ation of nuclear proteins and role of poly(ADP-ribose) polymerase in the early stages of apoptosis. J Biol Chem 273(22):13703-13712.
28. Wang L, et al. (2012) Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells. PLoS ONE 7(9):e44265.